If you are currently taking Mounjaro (tirzepatide) and considering a switch to Wegovy (semaglutide), you probably have questions. Perhaps your supply of Mounjaro has been affected by stock issues, or you are experiencing side effects that you hope a different medication might resolve. Maybe your prescriber has suggested Wegovy as an alternative, or you have simply heard enough about both medications to wonder which suits you better.
Whatever the reason, switching between weight loss injections is not as straightforward as swapping one for another. These are different medications with different mechanisms, different dosing schedules, and different side effect profiles. A well-managed transition requires clinical oversight and some understanding of what to expect.
This guide covers the key differences between the two medications, how the switching process typically works, what the evidence says about comparative effectiveness, and the practical questions that most patients want answered.
Understanding the Two Medications
Before discussing the switch itself, it helps to understand what makes Mounjaro and Wegovy different, and what they have in common.
Wegovy (Semaglutide)
Wegovy contains semaglutide, a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is a naturally occurring hormone released by the gut after eating. It signals to the brain that you are full, slows gastric emptying, and helps regulate blood sugar levels.
Semaglutide mimics this hormone at much higher concentrations than your body naturally produces, resulting in significantly reduced appetite, prolonged feelings of fullness, and reduced food intake. Wegovy is administered as a weekly subcutaneous injection and is available in five dose strengths: 0.25mg, 0.5mg, 1mg, 1.7mg, and 2.4mg.
Clinical trials, particularly the STEP programme, demonstrated an average weight loss of approximately 15 percent of body weight over 68 weeks at the highest dose. Wegovy is manufactured by Novo Nordisk and has been approved in the UK for weight management since early 2022.
Mounjaro (Tirzepatide)
Mounjaro contains tirzepatide, which works on two hormone receptors rather than one. It activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual-action mechanism is thought to provide enhanced appetite suppression and metabolic benefits compared to GLP-1 agonists alone.
Like Wegovy, Mounjaro is a weekly subcutaneous injection. It is available in six dose strengths: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg. Clinical trials, specifically the SURMOUNT programme, showed average weight losses of 15 to 22 percent of body weight depending on the dose used, with the highest doses producing the most substantial results.
Key Differences
| Feature | Wegovy (Semaglutide) | Mounjaro (Tirzepatide) |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | GLP-1 + GIP dual receptor agonist |
| Manufacturer | Novo Nordisk | Eli Lilly |
| Dose range | 0.25mg to 2.4mg | 2.5mg to 15mg |
| Average weight loss (trials) | ~15% of body weight | ~15-22% of body weight |
| Injection frequency | Once weekly | Once weekly |
It is worth noting that there are currently no published head-to-head clinical trials directly comparing Wegovy and Mounjaro for weight loss in the same study population. The figures above come from separate trial programmes with different participant demographics, so direct comparison should be made cautiously.
Why People Switch from Mounjaro to Wegovy
There are several legitimate clinical and practical reasons why a patient might transition from Mounjaro to Wegovy:
Supply and Availability Issues
Both medications have experienced intermittent supply disruptions in the UK. When Mounjaro is unavailable or certain dose strengths are out of stock, switching to Wegovy may be preferable to interrupting treatment entirely. Treatment gaps can lead to weight regain and loss of momentum, so maintaining some form of GLP-1 therapy is often clinically preferred.
Side Effect Management
While Mounjaro and Wegovy share many common side effects, including nausea, constipation, and gastrointestinal discomfort, individual responses vary considerably. Some patients who experience persistent or troublesome side effects on tirzepatide find that semaglutide is better tolerated, or vice versa. The different receptor profile may account for some of this variation.
Clinical Recommendation
Your prescriber may recommend a switch based on your overall clinical picture. Factors that might influence this decision include how your body has responded to Mounjaro, any metabolic changes observed during treatment, cost considerations, and your individual treatment goals.
Weight Maintenance
Some patients who have reached or approached their target weight on Mounjaro switch to Wegovy for the maintenance phase. This decision might be driven by dosing flexibility, cost, or clinical judgement about which medication best suits the maintenance phase of treatment.
How the Switch Works in Practice
Switching from Mounjaro to Wegovy is not simply a matter of stopping one injection and starting another on the same day. A clinical team will carefully manage the transition to ensure it is safe and effective.
The Washout Period
Most prescribers recommend a gap of approximately three weeks between your last Mounjaro injection and your first Wegovy injection. This allows tirzepatide to substantially clear from your system before semaglutide is introduced.
The purpose of this washout period is to reduce the risk of compounding side effects from having two different GLP-1 agonists active in your body simultaneously. Both medications can cause gastrointestinal symptoms, and overlapping their effects could intensify these significantly.
During the washout period, you may notice your appetite beginning to return as tirzepatide levels decline. This is expected and temporary. Maintaining your established dietary patterns during this gap is important but can require more conscious effort without pharmacological support.
Determining Your Starting Dose
Your starting dose of Wegovy will depend on several factors that your clinical team will assess:
- Your Mounjaro dose history: If you were on a higher dose of Mounjaro with good tolerance, you may be able to start Wegovy at a higher dose than the standard 0.25mg initiation. However, this is not guaranteed, as the two medications are not directly equivalent milligram-for-milligram.
- Your side effect experience: If you had significant gastrointestinal side effects on Mounjaro, starting Wegovy at a lower dose allows your body to adjust more gradually.
- Your treatment goals: Whether you are in the active weight loss phase or transitioning to maintenance will influence the target dose.
- Your overall health profile: Other medical conditions, concurrent medications, and general health all factor into dosing decisions.
Dose Escalation
If you start on a lower dose, your prescriber will typically follow Wegovy’s standard dose escalation schedule, increasing the dose every four weeks as tolerated. The standard escalation pathway is:
- 0.25mg weekly for 4 weeks
- 0.5mg weekly for 4 weeks
- 1mg weekly for 4 weeks
- 1.7mg weekly for 4 weeks
- 2.4mg weekly (maintenance dose)
However, if your clinical team determines that you can safely start at a higher dose based on your Mounjaro history, some of these early escalation steps may be skipped. This is a clinical judgement that should not be made independently.
What to Expect During the Transition
Switching medications is not a reset to zero, but it is an adjustment period that requires some patience and realistic expectations.
Side Effects
Even if you tolerated Mounjaro well, you may experience some side effects when starting Wegovy. The most common include:
- Nausea, particularly in the first few weeks at each new dose level
- Constipation or diarrhoea
- Abdominal discomfort or bloating
- Headache
- Fatigue
- Reduced appetite, though this is typically the desired effect
These side effects tend to be most pronounced during the first one to two weeks at each dose and usually diminish as your body adjusts. They are generally manageable and should not be a reason to discontinue without discussing with your prescriber.
According to the NHS information on semaglutide, most people find that gastrointestinal side effects improve within a few weeks. Staying well hydrated, eating smaller meals, and avoiding very rich or fatty foods can all help manage symptoms during this period.
Weight Loss Trajectory
Your weight loss may temporarily slow or plateau during the transition, particularly during the washout period and while building up to a therapeutic dose of Wegovy. This is normal and does not indicate that Wegovy is not working for you. Once you reach your maintenance or target dose, weight loss typically resumes at a rate comparable to your experience on Mounjaro.
Some patients find that Wegovy produces slightly different patterns of weight loss compared to Mounjaro. The rate may differ, the pattern of loss may be less linear, or the effects on appetite and food preferences may feel subtly different. These variations reflect the different pharmacological profiles of the two medications and are not cause for concern.
Appetite Changes
You may notice differences in how Wegovy affects your appetite compared to Mounjaro. Because tirzepatide acts on two receptor types (GLP-1 and GIP) while semaglutide acts on one (GLP-1 only), the quality of appetite suppression can feel different. Some patients describe Mounjaro’s effect as a more pronounced “switch off” of hunger, while Wegovy’s effect feels more like a gradual dimming. Others notice no meaningful difference.
These subjective differences are real and valid, but they do not necessarily predict effectiveness. Both medications produce clinically significant appetite suppression and weight loss in the majority of patients.
Considering a Switch?
Evernu’s prescribers can help you navigate the transition between weight loss medications safely. We provide personalised clinical guidance for patients across England, Scotland, Wales, and Northern Ireland, ensuring that any medication change is managed with your health and goals at the centre.
Explore our weight loss treatments or check your eligibility today.
Dose Conversion Guidance: Mounjaro to Wegovy
One of the most common questions patients ask is how their Mounjaro dose translates to an equivalent Wegovy dose. It is important to understand that there is no official, validated dose conversion table between tirzepatide and semaglutide. The two medications work differently and are not directly interchangeable on a milligram-for-milligram basis.
However, prescribers use general clinical guidelines to determine an appropriate starting point. These are based on the relative potency of each medication, the patient’s tolerance history, and their treatment goals. As a rough framework:
- Mounjaro 2.5mg to 5mg: Typically maps to starting Wegovy at 0.25mg to 0.5mg
- Mounjaro 7.5mg to 10mg: May allow starting Wegovy at 0.5mg to 1mg
- Mounjaro 12.5mg to 15mg: May allow starting Wegovy at 1mg to 1.7mg
Important: These are general guidelines only. Your actual starting dose should be determined by your prescriber based on your complete clinical picture. Factors including side effect history, concurrent medications, renal function, and treatment objectives all influence this decision. Do not attempt to determine your own dose conversion.
Benefits of Switching to Wegovy
While the decision to switch should be clinically driven rather than preference-based, there are several potential benefits that patients may experience after moving to Wegovy:
Cardiovascular Benefits
Semaglutide has the most robust cardiovascular evidence of any GLP-1 agonist currently available. The SELECT trial, which studied semaglutide in people with overweight or obesity and established cardiovascular disease, demonstrated a 20 percent reduction in major adverse cardiovascular events. This evidence contributed to NICE’s decision to recommend semaglutide for certain patient groups.
Established Safety Profile
Semaglutide has been available for longer than tirzepatide, first as Ozempic for type 2 diabetes and subsequently as Wegovy for weight management. This longer track record means there is more real-world safety data available, which some patients and clinicians find reassuring.
Different Side Effect Profile
While both medications share a similar range of potential side effects, individual tolerability can differ significantly. Patients who experience specific side effects on Mounjaro may find these are reduced or absent on Wegovy, though the reverse is also possible. The only way to know how you will respond is under supervised clinical trial of the medication.
Blood Sugar Management
Both medications improve blood sugar control, but semaglutide has extensive data specifically in patients with type 2 diabetes. For patients who have both weight management and glycaemic control goals, Wegovy may offer particular advantages depending on their clinical profile.
Potential Challenges of the Switch
It would not be balanced to discuss only the potential benefits. There are genuine challenges that some patients encounter when switching:
- Dose escalation time: If you need to start Wegovy at a low dose and titrate up, it may take several months to reach a fully therapeutic dose, during which weight loss may slow.
- New side effects: Even if you tolerated Mounjaro well, you may experience side effects with Wegovy as your body adjusts to a different medication.
- Psychological adjustment: Changing a medication that has been working well can be anxiety-inducing. Patients sometimes worry about losing the progress they have made.
- Temporary weight fluctuation: The washout period and dose escalation can lead to temporary weight gain or stalls that can be frustrating.
Being aware of these possibilities in advance helps you prepare for them rather than being caught off guard. Most of these challenges are temporary and resolve as you settle into the new medication.
When Switching May Not Be Appropriate
Not everyone is a suitable candidate for switching from Mounjaro to Wegovy. Situations where caution is warranted include:
- Known allergy or hypersensitivity to semaglutide or any of Wegovy’s excipients
- Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
- Severe gastrointestinal conditions that might be exacerbated by a new GLP-1 agonist
- Current pregnancy or planning to become pregnant
Your prescriber will assess these and other factors before recommending or approving a switch. Full transparency about your medical history is essential for safe prescribing.
Making the Most of Your Transition
If you and your clinical team decide that switching to Wegovy is the right course, there are several things you can do to support a smooth transition:
- Maintain your dietary habits during the washout period. The gap between medications is when old eating patterns are most likely to resurface. Plan your meals, keep to regular eating times, and be particularly mindful of portions.
- Stay active. Exercise helps manage appetite, mood, and weight stability during the transition. It also provides structure during a period that can feel uncertain.
- Track your symptoms. Keep a brief daily note of any side effects, appetite changes, and general well-being. This information is valuable for your prescriber when making dose adjustment decisions.
- Be patient with the process. The transition takes time, typically six to twelve weeks before you are on a stable, therapeutic dose. Comparing your progress during this period to your peak results on Mounjaro is unhelpful and unrealistic.
- Stay in communication with your clinical team. Report any concerns, unusual symptoms, or significant changes in your condition. Timely communication allows for timely adjustments.
Frequently Asked Questions
Do I need to wait between stopping Mounjaro and starting Wegovy?
Yes. Most prescribers recommend a washout period of approximately three weeks between your last Mounjaro injection and your first Wegovy injection. This allows tirzepatide to substantially clear your system before introducing semaglutide, reducing the risk of compounding gastrointestinal side effects. Your clinical team will advise on the exact timing based on your individual circumstances and the dose you were taking.
Can I start Wegovy at the lowest dose if I was on a high dose of Mounjaro?
Yes, you can. Starting at the lowest dose (0.25mg) is always an option and may be preferred if you experienced significant side effects on Mounjaro or if you want to take a cautious approach. However, if you tolerated Mounjaro well at higher doses, your prescriber may recommend starting Wegovy at a higher dose than 0.25mg to avoid an extended period of sub-therapeutic dosing. This is a clinical decision that should be made with your prescriber.
Will I gain weight during the switch?
Some weight fluctuation during the transition is possible, particularly during the washout period when neither medication is at full effect. However, this is typically modest and temporary. Maintaining your dietary habits and exercise routine during the transition helps minimise any weight gain. If you do gain a small amount, it is usually recovered once you reach a therapeutic dose of Wegovy.
Can I switch to Wegovy if my BMI has dropped below 30?
Wegovy is approved for adults with a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related health condition such as high blood pressure, type 2 diabetes, polycystic ovary syndrome, or obstructive sleep apnoea. If your BMI has dropped below 30 while on Mounjaro, you may still be eligible for Wegovy if you have a qualifying comorbidity. Your prescriber will assess your eligibility based on your current clinical picture.
Is Wegovy as effective as Mounjaro for weight loss?
Both medications produce clinically significant weight loss. In their respective clinical trials, Mounjaro showed slightly higher average weight loss percentages at maximum doses compared to Wegovy. However, these trials had different participant populations and study designs, making direct comparison difficult. Individual responses vary considerably, and some patients do better on semaglutide than tirzepatide and vice versa. Effectiveness for any individual depends on many factors beyond the medication itself, including diet, exercise, adherence, and metabolic response.
How long can I stay on Wegovy?
There is no fixed maximum duration for Wegovy treatment. Long-term studies have demonstrated safety and continued efficacy over periods exceeding two years. The decision about treatment duration should be made with your prescriber based on ongoing clinical benefit, side effect profile, and your individual weight management goals. Many clinicians view weight management as a chronic condition that may benefit from ongoing pharmacological support, similar to how blood pressure or cholesterol medications are prescribed indefinitely when clinically appropriate.
